Ronald Todd Plott Acquires 15,000 Shares of Phio Pharmaceuticals (NASDAQ:PHIO) Stock

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Director Ronald Todd Plott purchased 15,000 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was bought at an average price of $1.14 per share, for a total transaction of $17,100.00. Following the purchase, the director owned 15,000 shares in the company, valued at approximately $17,100. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Phio Pharmaceuticals Trading Up 9.5%

Shares of PHIO stock opened at $1.15 on Thursday. The stock has a market capitalization of $13.36 million, a price-to-earnings ratio of -0.89 and a beta of 0.82. Phio Pharmaceuticals Corp. has a 12-month low of $0.81 and a 12-month high of $4.19. The stock’s 50-day moving average price is $1.04 and its 200-day moving average price is $1.12.

Phio Pharmaceuticals (NASDAQ:PHIO) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.36). As a group, research analysts predict that Phio Pharmaceuticals Corp. will post -1.41 EPS for the current fiscal year.

Hedge Funds Weigh In On Phio Pharmaceuticals

A hedge fund recently raised its position in Phio Pharmaceuticals stock. Geode Capital Management LLC lifted its position in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) by 60.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 92,638 shares of the company’s stock after purchasing an additional 34,732 shares during the period. Geode Capital Management LLC owned 0.86% of Phio Pharmaceuticals worth $97,000 at the end of the most recent quarter. 57.31% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Phio Pharmaceuticals in a report on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Phio Pharmaceuticals has an average rating of “Hold” and a consensus price target of $14.00.

About Phio Pharmaceuticals

Phio Pharmaceuticals, Inc (NASDAQ: PHIO) is a clinical‐stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next‐generation RNAi compounds with potential applications in oncology and immuno‐oncology.

Phio’s TRiMTM platform is designed around the delivery of synthetic, double‐stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion.